Sign In
Buy DGX
$233.01
-1.29 (-0.551%)
At Close: Jul 31, 2026
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term
10:41am, Wednesday, 06'th May 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Quest Diagnostics Prices $500 Million of Senior Notes
04:10pm, Monday, 27'th Apr 2026
SECAUCUS, N.J., April 27, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX) (the "Company"), a leader in diagnostic information services, today announced the pricing of a public offering
AEGON ASSET MANAGEMENT UK Plc Decreases Stake in Quest Diagnostics Incorporated $DGX
03:09am, Sunday, 26'th Apr 2026
AEGON ASSET MANAGEMENT UK Plc cut its holdings in Quest Diagnostics Incorporated (NYSE: DGX) by 23.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Se
Quest Diagnostics: Good Q1, Solid Business, Steady Share Price Upside Likely
10:53am, Friday, 24'th Apr 2026
Quest Diagnostics delivered Q1 2026 revenue of $2.9 billion (+9.2% YoY) and EPS of $2.24 (+15.5% YoY), but shares dipped post-earnings. DGX maintains a strong core business with high barriers to entry
Quest Diagnostics Incorporated $DGX Stock Holdings Decreased by Cwm LLC
03:46am, Friday, 24'th Apr 2026
Cwm LLC lessened its position in Quest Diagnostics Incorporated (NYSE: DGX) by 28.4% in the undefined quarter, according to the company in its most recent filing with the SEC. The institutional invest
Here's Why Quest Diagnostics (DGX) is a Strong Momentum Stock
10:51am, Wednesday, 22'nd Apr 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Earnings
10:27am, Wednesday, 22'nd Apr 2026
Quest Diagnostics Incorporated (NYSE:DGX) on Tuesday reported upbeat earnings for the first quarter on Tuesday.
Is Quest Diagnostics Inc (DGX) Overvalued After 4.5% Rally? GF Value Says Overvalued
05:53pm, Tuesday, 21'st Apr 2026
On April 21, 2026, Quest Diagnostics Inc (DGX) shares rose 4.5% to a current price of $205.04. This move is part of a broader uptrend, with the stock experienci
Quest Diagnostics Incorporated (DGX) Q1 2026 Earnings Call Transcript
11:20am, Tuesday, 21'st Apr 2026
Quest Diagnostics Incorporated (DGX) Q1 2026 Earnings Call Transcript
Quest Diagnostics' Q1 Earnings & Revenues Top Estimates, Stock Up
09:56am, Tuesday, 21'st Apr 2026
DGX posts Q1 2026 earnings and revenue beat, with adjusted EPS up 13% and shares rising in pre-market trading.
Quest Diagnostics (DGX) Q1 Earnings and Revenues Top Estimates
08:56am, Tuesday, 21'st Apr 2026
Quest Diagnostics (DGX) came out with quarterly earnings of $2.5 per share, beating the Zacks Consensus Estimate of $2.37 per share. This compares to earnings of $2.21 per share a year ago.
Quest Diagnostics raises full-year forecast, posts strong quarter on testing demand
07:42am, Tuesday, 21'st Apr 2026
Quest Diagnostics on Tuesday raised its forecast for 2026 profit and revenue after posting first-quarter results above Wall Street estimates, citing resilient demand for routine diagnostic testing.
Quest Diagnostics Reports First Quarter 2026 Financial Results; Raises Revenue and EPS Guidance for Full Year 2026
06:47am, Tuesday, 21'st Apr 2026
First quarter revenues of $2.90 billion, up 9.2% from 2025, with 9.0% organic revenue growth First quarter reported diluted earnings per share ("EPS") of $2.24, up 15.5% from 2025; and adjusted dilute
Quest Diagnostics (DGX) is a Top-Ranked Value Stock: Should You Buy?
10:42am, Monday, 20'th Apr 2026
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
City of Hope to Evaluate Quest Diagnostics' Haystack MRD® for Guiding Patient Management in Multiple Cancers
09:00am, Thursday, 16'th Apr 2026
Fourteen City of Hope sites across the U.S. participating in research using the Haystack MRD ctDNA Test in patients with breast, colorectal, ovarian, and prostate cancer SECAUCUS, N.J. and LOS ANGELES
